Develops drugs for autoimmune diseases and cancer.
Jun 2026Revenue $54.6M/yrExpenses $195M/yr
No trendCash runway ≈ 2.9 years from Jun 2026
Figures by year
When will Nektar Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $54.6M and expenses $195M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $55.2M | $195M | −$140M |
| Dec 2024 | $98.4M | $204M | −$105M |
| Dec 2023 | $90.1M | $354M | −$264M |
| Dec 2022 | $92.1M | $468M | −$376M |
| Dec 2021 | $102M | $548M | −$446M |
| Dec 2020 | $153M | $578M | −$425M |
| Dec 2019 | $115M | $555M | −$440M |
| Dec 2018 | $1.19B | $505M | $688M |
| Dec 2017 | $308M | $367M | −$59.6M |
| Dec 2016 | $165M | $278M | −$113M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.